Lercanidipine
From Wikipedia, the free encyclopedia
 |
|
|
Lercanidipine
|
|
| Systematic (IUPAC) name | |
| methyl[2-(3,3-diphenylpropyl-methyl-amino)- 1,1-dimethyl-ethyl] 2,6-dimethyl- 4-(3-nitrophenyl)- 1,4-dihydropyridine-3, 5-dicarboxylate | |
| Identifiers | |
| CAS number | |
| ATC code | C08 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C36H41N3O6 |
| Mol. mass | 611.727 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Lercanidipine is a calcium channel blocker of the dihydropyridine class.
It is sold under various commercial names including Zanidip.
[edit] Further reading
- Lin T, Voon W, Yen H, Huang C, Su H, Lai W, Sheu S (2006). "Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters.". Kaohsiung J Med Sci 22 (4): 177–83. PMID 16679299.
- Martinez M, Lopes L, Coelho E, Nobre F, Rocha J, Gerlach R, Tanus-Santos J (2006). "Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension.". J Cardiovasc Pharmacol 47 (1): 117–22. doi:. PMID 16424795.
- Agrawal R, Marx A, Haller H (2006). "Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension.". J Hypertens 24 (1): 185–92. doi:. PMID 16331117.
[edit] External links
|
|||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
